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ABSTRACT 
 
Background: Potent P2Y12 inhibitors may offer enhanced benefit against thrombotic events in 
complex percutaneous coronary intervention (PCI). We examined prasugrel use and outcomes by 
PCI complexity, as well as analyzing treatment effects by thienopyridine type. 
Methods: PROMETHEUS was a multicenter observational study comparing clopidogrel vs. 
prasugrel in acute coronary syndrome patients undergoing PCI (n = 19,914). Complex PCI was 
defined as PCI of the left main, bifurcation lesion, moderate-severely calcified lesion or total stent 
length ≥30mm. Major adverse cardiac events (MACE) were a composite of death, myocardial 
infarction, stroke or unplanned revascularization. Outcomes were adjusted using multivariable Cox 
regression for impact of PCI complexity and propensity-stratified analysis for effect of thienopyridine 
type.  
Results: The study cohort included 48.9% (n=9,735) complex and 51.1% (n=10,179) non-complex 
patients. Second generation DES were used in 70.1% complex and 66.2% non-complex PCI 
patients (p <0.0001). Complex PCI was associated with greater adjusted risk of 1-year MACE (HR 
1.29, 95% CI 1.20-1.39, p <0.001). Prasugrel was prescribed in 20.7% of complex and 20.1% of 
non-complex PCI patients (p=0.30). Compared to clopidogrel, prasugrel significantly decreased 
adjusted risk for 1-year MACE in complex PCI (HR 0.79, 95% CI 0.68-0.92) but not non-complex 
PCI (HR 0.91, 95% CI 0.77-1.08), albeit there was no evidence of interaction (p interaction =0.281).  
Conclusions: Despite the use of contemporary techniques, ACS patients undergoing complex PCI 
had significantly higher rates of 1-year MACE. Adjusted magnitude of treatment effects with 
prasugrel versus clopidogrel were consistent in complex and non-complex PCI without evidence of 
interaction.  
 
Funding sources: The PROMETHEUS study was sponsored and funded by Daiichi Sankyo, Inc. 
and Eli Lilly and Company. 
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BRIEF SUMMARY:  
In this analysis from the PROMETHEUS ACS registry (n = 19,914), complex PCI (PCI of left main/ 
bifurcation/ moderate-severely calcified lesion/ stent length ≥30mm) was associated with greater 
risk of 1-year MACE (death, myocardial infarction, stroke or unplanned revascularization; HR 1.29 
[1.20-1.39]). Treatment effects with prasugrel vs. clopidogrel for risk of 1-year MACE were 
consistent in complex (HR 0.79 [0.68-0.92]) and non-complex PCI (HR 0.91 [0.77-1.08] (p 
interaction =0.281).  
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INTRODUCTION 
Percutaneous coronary intervention (PCI) in complex lesion subsets is associated with high 
thrombotic risk and greater susceptibility for both stent related and non-related short and long-term 
adverse events [1-3]. There is no universal definition for complex PCI and different classifications 
using combinations of lesion and procedural characteristics account for 10%- 50% of all PCI 
patients in current clinical practice [2-4]. In particular, PCI of the left main, bifurcation target lesion, 
moderate or severely calcified lesion or stent implantation of ≥30mm are procedural parameters 
correlated with greater event rates in prior studies [5-8]. Other authors have also attributed complex 
PCI status to chronic total occlusion (CTO) PCI, saphenous vein graft (SVG) PCI, use of rotablation 
atherectomy, target lesion with thrombus, tortuous target vessel, ultralong stent length >60mm, or 
factors based on total number of lesions treated or stents implanted [3, 4, 9-11]. Notwithstanding 
these anatomical variances in definition, risk may be further compounded in the setting of acute 
coronary syndromes (ACS) [12]. There are currently no outcomes data by PCI complexity in large 
ACS cohorts treated with contemporary PCI technologies. Furthermore, whether use of potent 
antiplatelet therapies provides preferential benefit to mitigate risk of recurrent thrombotic events 
following PCI in such high-risk patients has not been investigated. 
Potent P2Y12 therapies such as prasugrel and ticagrelor result in rapid, uniform and more 
potent platelet inhibition than clopidogrel with significantly reduced risk of 1-year ischemic outcomes 
[13, 14]. These agents are also recommended in guidelines for treatment of ACS patients 
undergoing PCI[15, 16]. However, the potential role of these potent agents has not been 
systematically examined by PCI complexity in randomized trials, thus specific recommendations by 
anatomical risk are presently lacking. Moreover, the decision for selection of potent inhibitors 
following complex PCI may be outweighed by concomitant risk of bleeding,  thus negating the net 
benefit of such therapies [13, 14, 17].  
We conducted a post-hoc analysis from a multicenter observational study of 19,914 patients 
undergoing ACS PCI in 8 academic US centers 1) to analyze 1-year outcomes by PCI complexity, 
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and 2) to examine the patterns of prasugrel use and to assess 1-year outcomes by thienopyridine 
type and PCI complexity. 
METHODS 
Study sample 
The PROMETHEUS study was a multicenter observational study including patients undergoing PCI 
between 1 January 2010 to 30 June 2013 at 8 academic US centers that maintained a prospective 
PCI database with 1-year follow-up [18]. The institutional ethics committees of all centers approved 
the study. All data were prospectively collected and then retrospectively extracted and harmonized 
for analysis. The data fields extracted followed standardized definitions of the National 
Cardiovascular Data Registry (NCDR) Catheterization PCI database and were jointly agreed to by 
the study investigators. The main study was designed to compare use of prasugrel and clopidogrel 
in all-comer ACS PCI. Management of data quality, statistical analyses and results reporting were 
the responsibility of the Data Coordinating Center at the Icahn School of Medicine at Mount Sinai, 
New York. The sponsors did not have access to patient-level data. 
 The study population included all patients undergoing PCI for ACS and treated with dual 
antiplatelet therapy (DAPT) with aspirin and either clopidogrel or prasugrel. The current analysis 
was stratified by the PCI complexity as complex vs. non-complex using the study definition (Figure 
1). The PCI procedure and related management was carried out per usual standard of care and at 
the discretion of the treating physicians at each site. Prescription of prasugrel or clopidogrel in 
individual patients was also directed by the treating physician. 
Endpoints and Definitions 
Complex PCI was defined as PCI with any 1 of the following characteristics: left main PCI location, 
bifurcation target lesion treated with any technique, moderate or severely target calcified target 
lesion or total implanted stent length ≥30mm. This definition was agreed on by the study authors 
based on prior studies indicating higher risk in these patient subsets [5-8]. The univariate and 
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multivariate adjusted risk associated with each component of the complex PCI definition for 90-day 
and 1-year MACE is shown in Supplementary Figure 1. All lesion characteristics including 
American College of Cardiology/ American Heart Association (ACC/AHA) lesion type were site 
reported and not adjudicated by an angiographic core laboratory. Variables used in other complex 
PCI definitions such as CTO PCI, SVG PCI, lesion length, vessel tortuosity, presence of thrombus, 
calcified lesions treated with rotablation atherectomy and bifurcation PCI requiring 2 stents were not 
available or could not be reliably ascertained from the dataset. SYNTAX score was not collected.  
The primary endpoint of the main study was 90-day major adverse cardiac events (MACE), 
composite of death, spontaneous myocardial infarction (MI), stroke or unplanned revascularization. 
This time point was selected since adherence at this stage was expected to continue to be high with 
low rates of thienopyridine switching. Secondary endpoints included the individual components of 
the primary endpoint, stent thrombosis (ST), and clinically significant bleeding which was defined as 
bleeding needing hospitalization or transfusion. Study endpoints were site reported in each center’s 
database and internally validated at site level but not centrally adjudicated.  
For this analysis we evaluated MACE and all secondary endpoints at 90 days and 1-year. Follow up 
was completed by phone, clinic visit or chart review as per standard of care by trained research staff 
at each site. 
We also examined the frequency of prasugrel use, prevalence of high-risk baseline features and the 
incidence of MACE and clinically significant bleeding in the overall population by number of complex 
features (0 to ≥3 for none, left main PCI, bifurcation PCI, moderate or severely calcified lesion, 
≥30mm stent length).  
STATISTICAL ANALYSIS 
Patients were grouped and compared by PCI complexity. Categorical data are presented as 
numbers and percentages and compared using the chi-square test. Continuous data are presented 
as means and standard deviations and compared using the parametric Student’s t test. Clinical 
event rates are presented using the Kaplan Meier method and compared using the log rank test. 
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Hazard ratios and confidence intervals for adjusted risk of 90-day and 1-year outcomes between 
patients with complex vs. non-complex PCI were generated using multivariable Cox regression 
methods (reference =non-complex PCI), adjusting for the following variables: age, African-American 
or other race, body mass index (BMI), diabetes, hypertension, estimated glomerular filtration rate, 
hemoglobin, prior PCI, coronary artery disease (CAD) presentation, multivessel disease, bivalirudin 
use, stent type, prasugrel use and center. Similarly adjusted hazard ratios and confidence intervals 
for MACE associated with each component of complex PCI were generated using multivariable Cox 
regression methods accounting for the following variables: age, African-American or other race, 
body mass index (BMI), diabetes, hypertension, estimated glomerular filtration rate, hemoglobin, 
prior PCI, coronary artery disease (CAD) presentation, bivalirudin use, stent type, prasugrel use and 
center.   
Further, adjusted hazard ratios and confidence intervals for risk of 90-day and 1-year outcomes with 
prasugrel vs. clopidogrel (reference = clopidogrel) among complex and non-complex PCI patients 
were generated using Cox proportional hazards regression stratified by propensity to receive 
prasugrel, with formal interaction testing between P2Y12 inhibitor treatment and PCI complexity. The 
propensity model included the following main effects: center, CAD presentation, diabetes, age, age 
squared, bivalirudin, smoking, gender, African-American race, hypertension, family history of CAD, 
prior PCI, prior coronary artery bypass surgery (CABG), prior peripheral arterial disease, prior 
congestive heart failure, prior cerebrovascular disease (CVD), stent length, stent diameter, 
glycoprotein IIb/IIIa inhibitor use, hypercholesterolemia, prior myocardial infarction, estimated 
glomerular filtration rate, stent type, body mass index (BMI), hemoglobin and the following 
interaction terms: center*procedural glycoprotein IIb/IIIa inhibitor use; BMI*hemoglobin; prior 
CVD*prior PCI; prior CVD*prior CABG. 
All data were analyzed using Stata version 14.0 (College station, Texas) or SAS version 9.4 (Cary, 
NC); p-values < 0.05 were considered significant. 
RESULTS 
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A total of 19,914 patients were included in the study, of whom 48.9% (n=9,735) underwent complex 
PCI and 51.1% (n=10,179) underwent non-complex PCI per the study definition. Tables 1 and 2 
show the baseline and procedural characteristics by PCI complexity. Complex PCI patients were 
older than non-complex PCI patients with a higher prevalence of diabetes, multi-distribution 
vasculopathy and multivessel disease. In the complex group, left main PCI was performed in 6.9%, 
bifurcation PCI in 20.1% and moderate or severe target lesion calcification was present in 28.9%. 
The mean stent length was 42.9mm in complex vs. 18.9mm in non-complex patients (p < 0.0001). 
Second generation drug eluting stents (DES) were used more often in complex PCI patients (70.1% 
vs. 66.2%, p <0.001). Complex PCI patients were more likely to be treated with glycoprotein IIb/IIIa 
inhibitors (24.0% vs. 21.9%, p =0.0002). Prasugrel was used in 20.7% of complex and 20.1% of 
non-complex PCI patients (p=0.30). The frequency of prasugrel by CAD presentation is shown in 
Figure 2. 
Loss to follow up was 8.4% at 90-days and 17.1% at 1-year. Supplementary Table 1 and Figure 3 
shows the clinical outcomes in complex and non-complex PCI groups. Both at 90-days and 1-year 
the incidences of MACE, death, MI, ST and unplanned revascularization were significantly greater 
in complex PCI patients. At 90-days the incidence of MACE was 10.6% in complex patients vs. 
7.2% in non-complex patients, adjusted HR 1.42, 95% CI 1.28-1.58, p <0.001. Analogously, the 
incidence of death in complex vs. non-complex patients was 3.1 vs. 1.7%, adjusted HR 1.48, 95% 
CI 1.20-1.83, p <0.001. At 1-year, the incidence of MACE was 22.0% in complex patients vs. 16.0% 
in non-complex patients, adjusted HR 1.29, 95% CI 1.20-1.39, p <0.001. The incidence of 1-year 
death in complex vs. non-complex patients was 6.7 vs. 4.6%, adjusted HR 1.25, 95% CI 1.09-1.43, 
p=0.002. A borderline trend was observed for greater clinically significant bleeding in complex PCI 
patients at 1-year (5.0% vs. 3.8%, adjusted HR 1.16, 95% CI 0.99-1.34, p =0.061). 
When we examined patients by increasing number of complex features from 0 to ≥ 3, the 
prevalence of baseline risk factors, and the incidence of both MACE and bleeding increased, 
whereas prasugrel use decreased in the same manner (Figure 4 and Supplementary Figure 2).  
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Effect of PCI complexity and thienopyridine type 
Supplementary Tables 2 and 3 show the baseline differences by PCI complexity and 
thienopyridine type. Prasugrel treated patients were younger and more often males in both groups 
with higher BMI and fewer comorbidities such as prior revascularization. However, prasugrel treated 
patients were more likely to present with troponin positive events. With respect to anatomical 
features, prasugrel treated complex patients had lower frequency of left main PCI and fewer 
moderate or severely calcified lesions compared to clopidogrel treated complex patients. 
Supplementary Table 4 and Figures 5-6 show the clinical outcomes by PCI complexity and 
thienopyridine type. At 90-days the incidence of MACE was lower with prasugrel vs. clopidogrel in 
complex and non-complex PCI patients, however adjusted treatment effects were not significantly 
different in both groups (complex PCI: 6.7% vs. 11.6%, HR 0.81, 95% CI 0.66-1.01, p = 0.057; non-
complex PCI: 4.8% vs. 7.7%, HR 0.99, 95% CI 0.76-1.27, p =0.910; p-interaction =0.624). At 1-
year, adjusted risk of MACE was lower with prasugrel vs. clopidogrel in complex PCI (13.3% vs. 
24.3%, HR 0.79, 95% CI 0.68-0.92, p = 0.002) but not in non-complex PCI (10.9% vs. 17.3%, HR 
0.91, 95% CI 0.77-1.08, p =0.292). Nevertheless, no evidence of interaction was observed between 
P2Y12 treatment and PCI complexity (p-interaction = 0.281). The effect of lowered MACE with 
prasugrel compared to clopidogrel in complex PCI patients was driven by lower risk of death. At 90-
days, adjusted risk of death was significantly lower with prasugrel vs. clopidogrel in complex PCI 
(0.8% vs. 3.7%, HR 0.48, 95% CI 0.27-0.85) but not non-complex PCI (0.4% vs. 2.0%, HR 0.75, 
95% CI 0.35-1.59); p-interaction=0.896. Similar results were noted for 1-year death with prasugrel 
vs. clopidogrel (complex PCI: 2.0% vs. 8.0%, HR 0.55, 95% CI 0.38-0.79; non-complex PCI: 1.6% 
vs. 5.4%, HR 0.76, 95% CI 0.50-1.16; p-interaction = 0.463). There were no adjusted differences in 
other secondary endpoints including MI or ST by thienopyridine type, regardless of PCI complexity. 
DISCUSSION 
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The main findings of the current analysis are as follows 1) complex ACS PCI comprising PCI of the 
left main, bifurcation target lesion, moderate or severely calcified target lesion or implantation of 
stent length ≥30mm was associated with significantly greater adjusted risk of 90-day and 1-year 
MACE, death, MI, ST and unplanned revascularization; 2) prasugrel was used in only one-fifth of 
ACS PCI patients regardless of PCI complexity; 3) compared to clopidogrel, prasugrel significantly 
decreased risk of 1-year MACE and death in complex PCI patients, albeit the adjusted magnitude of 
treatment effect with prasugrel versus clopidogrel was consistent in complex and non-complex PCI 
without evidence of interaction; 4) with increasing number of complex PCI features, the incidence of 
both ischemic and bleeding events increased whereas prasugrel use decreased, highlighting the 
counteracting risks and thus the unwillingness to prescribe potent P2Y12 inhibitors when perceived 
risk outweighs benefit. While decision for prasugrel prescription may be clear in the majority of ACS 
PCI patients presenting with a single complex PCI characteristic, physicians may perceive 
equipoise between ischemic benefit and potential harm from bleeding related to other comorbidities 
in patients with multiple complex features, necessitating more careful assessment for tailored 
prescription. 
Risks associated with complex PCI 
Complex PCI has been the subject of many recent reports [3, 4, 9-11] and although a universal 
definition is lacking several descriptions have been used, including some of the characteristics we 
utilized in our study definition, which have been shown to be associated with long-term adverse 
events in prior studies [4-9]. The left main subtends 100% of the left ventricular myocardial territory 
in a left dominant circulation and 70% in right dominant circulation [19]. While we did not have 
precise information on protected vs. unprotected left main lesions, nearly half of the left main lesions 
(n=301) were noted in patients without prior history of CABG. Majority of left main PCI involves the 
distal bifurcation, which is associated with the highest risk [5, 20, 21]. Indeed, bifurcation lesions 
remain associated with high rates of target lesion failure, even though use of 2nd generation DES 
has been observed to be protective [22]. Further, bifurcation lesions treated with a simple or 
complex strategy may be associated with greater risk than a non-bifurcation lesion due to procedure 
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related plaque shift, alteration of flow and risk of poor stent apposition[23]. Calcified lesions increase 
procedural technical difficulty requiring adjunctive use of intravascular imaging, rotablation 
atherectomy, guideliner support and higher inflation pressures to achieve stent optimization[24]. 
Further, several studies have shown that stent length >30mm is linked with greater risk for MACE, 
ST and target vessel revascularization [3, 7, 25]. Total stent length also serves as a surrogate for 
number of lesions and vessels treated and number of stents implanted. Although studies have also 
shown that number of vessels treated and number of stents implanted are associated with greater 
risk [4, 26], we were limited by missingness of information for number of stents. Furthermore 
multivessel PCI and number of stents were strongly associated with stent length ≥30mm, therefore 
we used the latter as a proxy variable. 
Indeed, we observed each component of our definition of complex PCI to be associated with 
higher adjusted risk of MACE both at 90-days and 1-year. However, other experts contend that 
lesion complexity should be considered in conjunction with systemic comorbidities, to allow 
comprehensive assessment of predicted risk[2]. Certainly patients undergoing complex PCI in the 
current study were more likely to have greater atherothrombotic risk factors including diabetes, prior 
MI and history of smoking, but they presented more frequently with unstable angina rather than 
troponin positive ACS.  
Both at 90-days and 1-year, complex PCI correlated with greater adjusted risk for MACE 
driven by death, MI and unplanned revascularization. Despite predominant 2nd generation DES use, 
complex patients were at significantly higher risk of MI and ST, thus PCI complexity was 
independently associated with both stent related and non-stent related thrombotic outcomes 
following PCI. Other studies have noted similar findings of greater adverse event rates attributed to 
PCI complexity [3, 4, 9]. However, mortality reductions exceeding reductions in MI observed in our 
study strongly suggest that residual confounding from unmeasured parameters may account for 
greater mortality in complex PCI patients. Although we observed a borderline trend for greater 
adjusted risk of bleeding in complex patients, this was not statistically significant. The recent 
complex PCI patient-level pooled analysis from 6 randomized controlled trials also did not 
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demonstrate greater hazard for bleeding in complex PCI, however the eligibility criteria of the 
included trials may have precluded enrollment of patients at highest risk of bleeding [4].  
Selecting patients for prasugrel 
Despite higher adjusted risk of MACE in complex PCI patients, use of prasugrel was notably similar 
in both groups. However, when examined by the number of complex PCI features, prasugrel use 
declined with rising PCI complexity. Conversely a stepwise increase was noted in the incidence of 
both MACE and bleeding from 0 to ≥3 complex features. Additionally, we observed that with 
advancing PCI complexity, the frequency of risk factors for bleeding where prasugrel use is 
generally not recommended per the Food and Drug administration label [27], specifically, age ≥ 75 
years, weight <60kg and history of prior cerebrovascular disease, gradually increased, providing a 
plausible explanation for the decrease in prescription rates. Moreover, other risk factors associated 
with bleeding such as prevalence of chronic kidney disease (CKD) and pre-existing anemia were 
higher in increasingly complex patients [28, 29]. In fact, these bleeding risks may not only influence 
prescription rates, but also adherence to antiplatelet therapy [30, 31]. Our study suggests that 
prasugrel, while prescribed more frequently in patients with one complex PCI characteristic, was 
less often used in the setting of multiple complex PCI features. Ongoing studies will examine 
whether a novel strategy of aspirin withdrawal and continued potent antiplatelet monotherapy yields 
benefit in complex PCI patients [32, 33]. Alternatively whether switching down from potent P2Y12 
therapy to clopidogrel after the first month is beneficial in high bleeding risk complex PCI patients is 
not known [34]. Importantly, the recent complex PCI pooled analysis suggested that longer DAPT 
duration was beneficial for MACE reduction in complex but not in non-complex PCI patients, albeit 
prolonged DAPT resulted in greater bleeding irrespective of PCI complexity[4]. In addition, DAPT 
included clopidogrel in majority of the patients in this meta-analysis, rather than potent P2Y12 
therapy. 
Interestingly, on propensity stratified analysis although we observed a benefit for lower 1-
year MACE and death with prasugrel vs. clopidogrel in complex patients, there was no evidence of 
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P2Y12 treatment interaction by PCI complexity. Moreover, there was no reduction in risk of MI or ST. 
This may be due to 1) limited sample size to demonstrate interaction; 2) selection bias resulting in 
healthier patients receiving prasugrel, who may not be at highest risk, affirming the well-described 
risk-benefit paradox [35]; 3) consideration of only high risk procedural characteristics in the study 
definition rather than high risk patient factors such as STEMI, diabetes or prior PCI where prasugrel 
may be most beneficial [13, 36, 37]; 4) other mechanisms at play to increase platelet reactivity and 
ischemic risk in complex PCI patients with diabetes and CKD, which may not be attenuated by 
P2Y12 inhibitors [38]; 5) adherence to medications was not assessed and decreased compliance or 
cessation of prasugrel and switching to clopidogrel may have been a contributor to the observed 
outcomes. However, adherence at 90-days is expected to be ≥90%; sensitivity analysis excluding 
patients switching treatment prior to discharge observed similar outcomes in the main study [18]. 
Limitations 
PROMETHEUS was an observational study and prospectively collected data were retrospectively 
extracted and although validated at site level, were not centrally adjudicated. Information on 
cardiovascular and non-cardiovascular causes of death was not available. We considered a 
definition for complex PCI based on site reported standard high-risk angiographic/procedural 
characteristics, which were not validated by a core lab. However each component was associated 
with greater adjusted hazard for early and late MACE. SYNTAX scores were not available and could 
not be used to support our definition of complex PCI. Although certain variables used in other 
reported definitions of complex PCI were unavailable, our results confirm the internal validity of the 
study definition demonstrating significantly greater risk of early and late outcomes in complex PCI 
patients. The sample size for this subgroup analysis was limited and hence the findings for the role 
of prasugrel in complex PCI are merely exploratory. Comparisons between prasugrel and 
clopidogrel may be influenced by unmeasured confounders resulting in treatment selection bias. We 
did not have information on adherence to antiplatelet therapy through 1-year follow-up. 
CONCLUSIONS 
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Complex PCI per the study definition comprised nearly 50% of ACS patients and was an 
independent predictor of 90-day and 1-year adjusted risk of MACE, MI, ST and death despite 
contemporary PCI techniques. Real world uptake of prasugrel across the participating academic 
centers from the United States was low in both complex and non-complex ACS PCI patients, in 
contrast to current ACS guidelines. Although prasugrel significantly decreased risk of 1-year MACE 
in complex PCI patients compared to clopidogrel, a P2Y12 treatment interaction was not observed 
by PCI complexity, therefore adequately powered randomized trial data are required to confirm 
these findings.  
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FIGURE LEGENDS 
 
 
Figure 1: Study Flow 
Figure 2: Frequency of prasugrel use by CAD presentation in complex and non-complex PCI 
groups 
Figure 3: Adjusted risk of 90-day and 1-year clinical outcomes in patients with complex vs. non-
complex PCI 
Figure 4: Frequency of prasugrel use, and incidence of MACE and clinically significant bleeding by 
increasing number of complex PCI features 
MACE, major adverse cardiovascular events 
Figure 5: Cumulative incidence of MACE and clinically significant bleeding by thienopyridine type 
and PCI complexity during 1-year follow-up 
MACE, major adverse cardiovascular events 
Figure 6: Propensity stratified 90-day and 1-year outcomes by thienopyridine type and PCI 
complexity 
Supplementary Figure 1: Unadjusted and adjusted risk of complex PCI components on 90-day 
and 1-year MACE 
MACE, major adverse cardiovascular events 
Supplementary Figure 2: Frequency of baseline clinical risks by increasing number of complex 
PCI features 
CKD, chronic kidney disease; CVD, cerebrovascular disease 
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TABLE 1: Baseline characteristics in patients undergoing Complex and Non-Complex PCI 
 
 
Complex PCI 
N = 9,735 
Non-Complex PCI 
N = 10,179 p-value 
Age, years, mean (SD) 65.23 ± 12.18 63.60 ± 12.31 <0.0001  
Female 3045(31.3%) 3259(32.0%) 0.2630  
African-American, n (%) 933(9.6%) 1192(11.7%) <0.0001 
BMI (kg/m2), mean (SD) 29.82 ± 6.17 30.02 ± 6.18 0.0226 
Diabetes, n (%) 3946(40.5%) 3634(35.7%) <0.0001  
• Diabetes on insulin 1283(13.2%) 1251(12.3%) 0.0781  
Hypertension, n (%) 8228(84.5%) 8153(80.1%) <0.0001  
Dyslipidemia, n (%) 8394(86.2%) 8295(81.5%) <0.0001  
Smoking, n (%) 2345(24.1%) 2661(26.1%) 0.0009 
Prior MI, n (%) 3100(31.8%) 2863(28.1%) <0.0001 
Prior PCI, n (%) 2520(25.9%) 2518(24.7%) 0.0623  
Prior CABG, n (%) 1866(19.2%) 1567(15.4%) <0.0001 
Prior cerebrovascular 
disease, n (%) 1294(13.3%) 1091(10.7%) <0.0001 
Prior CHF, n (%) 2328(23.9%) 1923(18.9%) <0.0001  
Left ventricular ejection 
fraction, %, mean (SD) 50.90 ± 13.86 52.31 ± 12.78 <0.0001  
Prior PAD, n (%) 1328(13.6%) 1103(10.8%) <0.0001  
Anemia, n (%) 1560 (16.0%) 1332 (13.1%) <0.0001 
CAD Presentation, n (%)  
  <0.0001  
• Unstable angina 5627(57.8%) 5589(54.9%)  
• NSTEMI 2666(27.4%) 2746(27.0%)  
• STEMI 1441(14.8%) 1844(18.1%)  
 
BMI: Body Mass Index; CABG: Coronary Artery Bypass grafting; CAD: Coronary Artery Disease; CHF: Congestive Heart Failure; 
CKD: Chronic Kidney Disease; MI: Myocardial Infarction; NSTEMI: Non ST-segment elevation myocardial infarction; PAD: Peripheral 
Artery Disease; PCI: Percutaneous Coronary Intervention; STEMI: ST-segment elevation myocardial infarction.  
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TABLE 2: Procedural characteristics in patients undergoing Complex and Non-Complex PCI 
 
Complex PCI 
N = 9,735 
Non-Complex PCI 
N = 10,179 p-value 
Multivessel disease, n (%) 5119(52.6%) 3277(32.2%) <0.001  
PCI vessel, n (%) 
  
<0.001  
• Left Main 667(6.9%) 0(0.0%) <0.001  
• Left anterior descending  4736(48.6%) 4159(40.9%) <0.001  
• Circumflex 3169(32.6%) 2725(26.8%) <0.001  
• Right coronary artery 3631(37.3%) 3166(31.1%) <0.001  
At least one B2/C type lesion, n (%) 8235(84.6%) 5371(52.8%) <0.001  
At least one lesion with moderate/severe 
calcification, n (%) 2771(28.5%) 0(0.0%) 
<0.001  
At least one bifurcation lesion, n (%) 2122(21.8%) 0(0.0%) <0.001  
Stent length ≥30mm, mean (SD) 7329 (75.6%) 0 (0.0%) <0.001  
Total stent length, mm, mean (SD) 42.94 ± 23.25 18.55 ± 5.45 <0.001  
Minimum stent diameter, mm, mean (SD) 2.91 ± 0.48 3.02 ± 0.51 <0.001  
Multivessel PCI, n (%) 2331(23.9%) 337(3.3%) <0.001 
≥3 vessels treated  291(3.0%) 8(0.07%) <0.001 
Number of lesions treated, mean (SD) 1.81 ± 0.85 1.12 ± 0.36 <0.001 
Number of stents implanted, mean (SD) 2.07 ± 1.03 1.09 ± 0.33 <0.001 
≥3 lesions treated 1515 (17.1%) 72 (0.8%) <0.001 
≥3 stents implanted 2036(24.5%) 50(0.5%) <0.001 
>60mm total stent length 1654(17.0%) 0(0.0%) <0.001 
Stent type, n (%) 
   
At least one 1st generation DES 1819(18.7%) 973(9.6%) <0.001  
At least one 2nd generation DES 6825(70.1%) 6736(66.2%) <0.001  
At least one BMS 1786(18.3%) 2709(26.6%) <0.001  
Procedural anticoagulation, n (%) 
   
Bivalirudin 7004(71.9%) 7465(73.3%) 00.0269 
GPI  2341(24.0%) 2225(21.9%)   0.0002 
LMWH 102(1.0%) 105(1.0%) 0.6153 
 
Numbers are presented as n (%) unless indicated otherwise. 
BMS, bare metal stent; DES, drug eluting stent; GPI, glycoprotein 2b3a inhibitor; LMWH, low molecular weight heparin; 
